ACC, Cipla: 66 stocks from Nifty 500 index are showing weakness on charts

Few pharma stocks are expected to weaken at higher levels.

buy, sell, stocks, share
Since their March 2020 lows, both Sensex and Nifty have jumped 80 per cent, each, NSE and BSE data show.
Avdhut Bagkar Mumbai
2 min read Last Updated : Dec 11 2020 | 12:19 PM IST
The domestic stock market is on a record-breaking spree. On Friday, the benchmark S&P BSE Sensex hit a fresh all-time high of 46,309.63 during the intra-day deals while NSE's Nifty scaled a record peak of 13,579.35. Since their March 2020 lows, both Sensex and Nifty have jumped 80 per cent, each, NSE and BSE data show. 

However, amid this relentless rally, few stocks are showing weakness on their respective technical parameters. For instance, as many as 66 stocks, including select pharma and cement counters, from the Nifty 500 index are expected to see profit-booking in the coming sessions.   

Some of these stocks are trading in the overbought condition of the Relative Strength Index (RSI) on the weekly scale while in others, one can see momentum on the Moving Average Convergence Divergence (MACD) exhibiting negative crossovers, as per the daily charts.

The next upside for these Nifty 500 stocks is possible only if they see an increase in volumes after crossing their selling pressure range. Stocks in the pharma index are weakening at higher levels, however, a strong move above their current resistance may see a next upward rally. But at the current levels, stocks such as Cipla, Jyothy Labs, Zydus Wellness from the pharma pack, and cement stocks such as ACC Limited, Shree Cement Limited, and Star Cement Limited, are indicating profit-booking.

Here is a list of 66 stocks from Nifty 500 index that are showcasing weakness.


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :pharma sctorsBuzzing stocksStock to watchMarketsCement

Next Story